MedTrace Logo

Characterization of the microVAScular Dysfunction in Covid-19 ARDS

NCT05074758 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-01-19

No results posted yet for this study

Summary

The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.

Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.

Conditions

  • ARDS, Human
  • COVID-19 Acute Respiratory Distress Syndrome

Interventions

DIAGNOSTIC_TEST

alveolar dead-space quantification

measurement of alveolar dead-space based on volumetric capnography

DIAGNOSTIC_TEST

Coagulation activation and impaired fibrinolysis explorations

blood sampling: * Fibrinolytic components * NETs components * Elastase-derived fragments of proteins of interest

DIAGNOSTIC_TEST

Endothelial activation / endothelial senescence

circulating endothelial cells, E-selectin, endoglin, LVEF-A, LVEFR-2, Angiopoietin -1 and -2, cKit and SDF-1 Willebrand factor (activity, antigen, multimeric analysis )

Sponsors & Collaborators

  • National Research Agency, France

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-Luc Diehl, PhD · AP-HP, Hôpital Européen Georges Pompidou, Paris

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2022-09-10
Completion
2022-09-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05074758 on ClinicalTrials.gov